Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Neoplasms × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Triple Negative Breast Neoplasms 2 Recurrence 1 Neoplasms 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Breast Neoplasms 1 Advanced Solid Malignancy, 1

Interventions

Gemcitabine 47 Paclitaxel 44 Cyclophosphamide 40 Carboplatin 38 pembrolizumab 37 Bevacizumab 36 Cisplatin 30 Fluorouracil 27 Docetaxel 27 Capecitabine 26 Nivolumab 25 Pemetrexed 22 Irinotecan 22 Oxaliplatin 21 Leucovorin 20 Dexamethasone 20 Sorafenib 18 Ipilimumab 18 Everolimus 17 Doxorubicin 16 fludarabine 15 Rituximab 15 Radiotherapy 15 Erlotinib Hydrochloride 15 Cetuximab 15 Albumin-Bound Paclitaxel 15 Prednisone 13 Lapatinib 13 130-nm albumin-bound paclitaxel 13 eribulin 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡